Ampio Pharmaceuticals (NYSEMKT: AMPE ) discloses ( 10-Q, page 23 ) that one of its directors received a subpoena from the SEC requesting documents and information related to its ongoing investigation into potential insider trading. More news on: Ampio Pharmaceuticals, Inc., Healthcare stoc...

ENGLEWOOD, Colo. , Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampion TM to treat Adults...

ENGLEWOOD, Colo. , Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled  "Evaluating the Efficacy and Safety of Ampion to tr...